Franck Drouet

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun et al. · Annals of Oncology · 2022 · 177 citations · Full text

Medicine, Oncology, Radiation Oncology +13

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

Jean Bourhis, Clément Sire, Yungan Tao et al. · Annals of Oncology · 2020 · 65 citations

Medicine, Oncology, Radiation Oncology +9

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Sun, Christian Sire, Yungan Tao et al. · Journal of Clinical Oncology · 2018 · 53 citations

Medicine, Oncology, Radiation Oncology +14

Severe radiotherapy-induced extracutaneous toxicity under vemurafenib

L. Peuvrel, Anne‐Lise Ruellan, F. Thillays et al. · European Journal of Dermatology · 2013 · 48 citations

Medicine, Oncology, Radiation Oncology +15

Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

V. Vendrely, C. Lemanski, P. Pommier et al. · Radiotherapy and Oncology · 2023 · 19 citations · Full text

Medicine, Oncology, Surgery +14